At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 505 enrolled

Drug / intervention

Nivolumab +8 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02998528

NCT02998528Phase 3Completed

Compare CT.gov

Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC

Bristol-Myers Squibb·interventional·Posted Dec 20, 2016·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating Nivolumab, Cisplatin, and 7 other interventions for Non Small Cell Lung Cancer. Completed, enrolled 505 participants across 138 sites in 15 countries.

Detailed Summary

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon Small Cell Lung Cancer

CountriesArgentina, Brazil, Canada, China, France, Greece, Hungary, Italy, Japan, Romania, South Korea, Spain, Taiwan, Turkey (Türkiye), United States

CollaboratorsOno Pharmaceutical Co., Ltd.

Timeline

Phase 3CompletedFinished

2017201820192020202120222023202420252026

First PostedDec 2016

Enrollment StartMar 2017

Primary CompletionSep 2021

Study CompletionDec 2024

TodayJul 2026

First PostedDec 20, 2016

Enrollment StartMar 4, 2017

Primary CompletionSep 8, 2021

Study CompletionDec 6, 2024

TodayJul 2, 2026

Enrollment to primary: 4.5 yearsPosted 9.5 years ago